Biotech Values

[iwfal]

ZGEN - It looks like the drug is on target to reach the market around the time when interferon therapies will be starting to become less relevant.

I asked a related question several months ago - are there any drugs seeking approval via a clinical program without IFN? Your answer at the time was no. Obviously there are the earliest possible signs that that is changing - but so far I've only seen one trial aimed at a no IFN treatment (albeit I haven't done a thorough scan through clinical trials.org)

Some more related questions (if you have info, great. If not it is something I need to look into):

1) As standalone agents how well do some of the candidates for a drug cocktail work? (This goes to whether there is a chance that they are so much better that they will make IFN obsolete)

2) SAEs for the drugs in trials - so far it appears that ribvarin(sp?) has more SAEs than IFN-L

PS I am not sure I would call it the 'slow lane'. Actually reasonably fast at this point - e.g. they started the ribivarin portion of the trial early (although I'll agree they were not terribly speedy up until the start of the phase ib). The question is whether that is fast enough.